Clinical Trial Update: Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating recombinant human keratinocyte growth factor (Palifermin) to reduce oral mucositis in patients with hematologic malignancies undergoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Oral Mucositis
• Stomatitis

Drugs mentioned

• Palifermin (palifermin)

Snippet

Sponsor: Amgen | Conditions: Stomatitis | Phase 3 | Status: COMPLETED